AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?Zacks Investment Research • 10/06/25
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential TremorPRNewsWire • 10/06/25
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.PRNewsWire • 09/30/25
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment OptionsPRNewsWire • 09/30/25
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing FacilityPRNewsWire • 09/29/25
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)PRNewsWire • 09/29/25
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?Zacks Investment Research • 09/26/25
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's DiseasePRNewsWire • 09/26/25
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for RheumatologistsGlobeNewsWire • 09/25/25